8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

                        Date of Report: November 2, 2004

                                 CYTOMEDIX, INC.
             (Exact name of registrant as it appears in its charter)

         Delaware                    0-28443                     23-3011702
- ----------------------------  ------------------------      --------------------
(State or other jurisdiction  (Commission File Number)         (IRS Employer
    of incorporation)                                       Indentification No.)

                         416 Hungerford Drive, Suite 330
                            Rockville, Maryland 20850
              (Address of principal executive offices and zip code)

                                 (301) 251-2815
              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act
      (17 CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))



Section 5--Corporate Governance and Management

Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers

(d) On November 1, 2004, Mr. James S. Benson accepted an appointment to fill a
vacancy on the Cytomedix, Inc. board of directors. Cytomedix issued the attached
press release announcing that Mr. Benson had accepted the appointment made by
the Cytomedix board of directors. The press release is filed as Exhibit 99.1 and
incorporated herein by reference.

Section 9--Financial Statements and Exhibits

Item 9.01  Financial Statements and Exhibits.

(c) Exhibits. The following Exhibit is furnished with this Current Report on
Form 8-K:

Exhibit No.       Description
- -----------       -----------

Exhibit 99.1      Press Release of Cytomedix, Inc., dated November 1, 2004.

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        CYTOMEDIX, INC.


                                        By: /s/ William Allender
                                           -------------------------------------
                                           William Allender
                                           Chief Financial Officer

Date: November 2, 2004

EX-99.1

Exhibit 99.1

     CYTOMEDIX, INC. APPOINTS JAMES S. BENSON, FORMER TOP EXECUTIVE AT FDA,
                           TO ITS BOARD OF DIRECTORS

ROCKVILLE, Maryland - November 1, 2004 - Cytomedix, Inc. (OTCBB:CYME) today
announced the appointment of James S. Benson to its board of directors, filling
a board vacancy.

"For more than twenty five years, Jim Benson has distinguished himself as a
leading healthcare industry professional, with extensive experience within the
regulatory environment. As Cytomedix continues to implement a strategy of
simultaneously conducting FDA-approved clinical trials for its Autologel(TM)
therapy, aggressively pursuing healthcare companies and practitioners infringing
on the company's patents and securing licensing/royalty agreements, we expect to
greatly benefit from Mr. Benson's experience and expertise," said Dr. Kshitij
Mohan, chief executive officer of Cytomedix.

Commenting on his appointment, James Benson stated, "Chronic wound care
treatment is a significant challenge for healthcare professionals. The company's
patented-technology offers tremendous potential for patients suffering from a
variety of these afflictions and I look forward to working with Kshitij and his
team in implementing Cytomedix's strategy and making this therapy widely
available to patients."

Benson retired from the Advanced Medical Device Association (AdvaMed, formerly
know as The Health Industry Manufacturers Association, HIMA), where he served as
executive vice president for Technical and Regulatory Affairs. Prior to that, he
held numerous senior positions at the Food and Drug Administration (FDA) over a
twenty-year period. He retired from the FDA as director of the Center for
Devices and Radiological Health (CDRH). Earlier, he served as deputy
commissioner of the FDA, and also as its acting commissioner for a one-year
period.

During his tenure with the FDA, he worked closely with other Federal Agencies,
especially the National Institutes of Health and the Centers for Disease Control
and Prevention.

He has also actively worked with the Congress in creating three separate pieces
of legislation affecting the FDA: The Food and Drug Modernization Act of 1997,
the Biomaterials Access Act of 1998, and the Medical Device User Fee and
Modernization Act of 2002.

Subsequent to his retirement from the FDA, he has served as a consultant for
numerous medical device companies and as an expert witness on several court
cases. He is a member of several professional societies and served as a board of
trustee for one organization.

Benson earned a Bachelor of Science degree in civil engineering from the
University of Maryland and a Master of Science degree in nuclear engineering
from the Georgia Institute of Technology.

About Cytomedix

Cytomedix, Inc. is a biotechnology company specializing in processes and
products derived from autologous platelet releasates. The company owns
proprietary technology for the creation of autologous platelet gel composed of
multiple growth factors and fibrin matrix. Additional information is available
at the company's website at www.cytomedix.com.



Forward Looking Statements

Statements contained in this press release not relating to historical facts are
forward-looking statements that are intended to fall with the safe harbor rule
for such statements under the Private Securities Litigation Reform Act of 1995.
The information contained in the forward-looking statements is inherently
uncertain, and Cytomedix's actual results may differ materially due to a number
of factors, many of which are beyond Cytomedix's ability to predict or control,
including among others, governmental regulation, acceptance by the medical
community and competition. These forward-looking statements are subject to known
and unknown risks and uncertainties that could cause actual events to differ
from the forward-looking statements. More information about some of these risks
and uncertainties may be found in the reports filed with the Securities and
Exchange Commission by Cytomedix, Inc.